Diversified Trust Co Purchases New Shares in Adaptive Biotechnologies Corporation $ADPT

Key Points

• Diversified Trust Co acquired 37,634 shares of Adaptive Biotechnologies Corporation in Q2, investing approximately $438,000.
• Recent analyst reports have generally been positive, with seven analysts rating the stock as a "Buy" and price targets increased to around $15.00.
• Adaptive Biotechnologies reported a revenue of $49.94 million for the last quarter, exceeding expectations and marking a 36.3% year-over-year increase despite a negative EPS of ($0.17).

Diversified Trust Co purchased a new stake in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 37,634 shares of the company's stock, valued at approximately $438,000.

Other large investors have also recently added to or reduced their stakes in the company. Blair William & Co. IL bought a new position in Adaptive Biotechnologies during the 1st quarter valued at $84,000. Personal CFO Solutions LLC bought a new position in Adaptive Biotechnologies during the 1st quarter valued at $84,000. Wealth Enhancement Advisory Services LLC bought a new position in Adaptive Biotechnologies during the 1st quarter valued at $87,000. Candriam S.C.A. bought a new position in Adaptive Biotechnologies during the 1st quarter valued at $90,000. Finally, Caxton Associates LLP bought a new position in Adaptive Biotechnologies during the 1st quarter valued at $93,000. 99.17% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ADPT has been the topic of a number of research analyst reports. Craig Hallum initiated coverage on shares of Adaptive Biotechnologies in a research note on Wednesday, June 18th. They set a "buy" rating and a $15.00 price objective on the stock. JPMorgan Chase & Co. increased their price objective on shares of Adaptive Biotechnologies from $10.00 to $14.00 and gave the company an "overweight" rating in a research note on Wednesday, August 6th. TD Cowen increased their price objective on shares of Adaptive Biotechnologies from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. Finally, Piper Sandler increased their price objective on shares of Adaptive Biotechnologies from $13.00 to $15.00 and gave the company an "overweight" rating in a research note on Wednesday, August 6th. Seven analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, Adaptive Biotechnologies presently has an average rating of "Moderate Buy" and a consensus price target of $12.38.

Adaptive Biotechnologies Trading Down 0.1%

Adaptive Biotechnologies stock opened at $13.93 on Wednesday. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -16.99 and a beta of 1.93. The company's 50-day moving average price is $12.18 and its two-hundred day moving average price is $10.19. Adaptive Biotechnologies Corporation has a 52 week low of $3.98 and a 52 week high of $14.48.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.07. The firm had revenue of $49.94 million for the quarter, compared to analysts' expectations of $49.40 million. Adaptive Biotechnologies had a negative net margin of 59.07% and a negative return on equity of 60.93%. Adaptive Biotechnologies's quarterly revenue was up 36.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.31) EPS. Research analysts expect that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.